

Title (en)  
NOVEL COMPOUND FOR TREATMENT OF TUMOR

Title (de)  
NEUE VERBINDUNG ZUR TUMORTHERAPIE

Title (fr)  
NOUVEAU COMPOSÉ DE TRAITEMENT DE TUMEUR

Publication  
**EP 1987838 A4 20100224 (EN)**

Application  
**EP 07702135 A 20070119**

Priority  
• CN 2007000203 W 20070119  
• CN 200610011246 A 20060120

Abstract (en)  
[origin: EP1987838A1] The present invention is directed to an anti-tumor protein coupled with a specific modifying reagent at a specific site to overcome the inherent deficiencies of the anti-tumor protein, such as a high antigenicity and a short half-time, and to overcome the deficiencies resulted from a non-specifically modifying method, such as inconsistent modified sites, inhomogeneous constitutes, significantly decreased activity and hard-to-control quality of the products, and to ultimately make it available for the treatment of tumors and production of anti-tumor medicaments.

IPC 8 full level  
**A61K 38/50** (2006.01); **A61P 35/00** (2006.01); **C12N 9/78** (2006.01); **C12N 9/96** (2006.01); **C12N 11/08** (2006.01)

CPC (source: EP US)  
**A61P 35/00** (2017.12 - EP); **A61P 35/04** (2017.12 - EP); **C12N 9/78** (2013.01 - EP US); **C12N 9/96** (2013.01 - EP US); **C12N 11/089** (2020.01 - EP US); **C12Y 305/03006** (2013.01 - EP US)

Citation (search report)  
• [A] WO 0183774 A2 20011108 - PHOENIX PHARMACOLOGICS INC [US], et al  
• [A] WO 2004001048 A1 20031231 - BIO CANCER TREATMENT INT LTD [CN], et al  
• [A] KOCHENDOERFER G: "CHEMICAL AND BIOLOGICAL PROPERTIES OF POLYMER-MODIFIED PROTEINS", EXPERT OPINION ON BIOLOGICAL THERAPY, vol. 3, no. 8, 2003, pages 1253 - 1261, XP008036528  
• [A] HOLTSBERG F W ET AL: "Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties", JOURNAL OF CONTROLLED RELEASE, vol. 80, no. 1-3, 2002, pages 259 - 271, XP004348640  
• [A] GAERTNER H F ET AL: "SITE-SPECIFIC ATTACHMENT OF FUNCTIONALIZED POLY(ETHYLENE GLYCOL) TOTHE AMINO TERMINUS OF PROTEINS", BIOCONJUGATE CHEMISTRY, vol. 7, no. 1, 1996, pages 38 - 44, XP002944821  
• [A] EDWARDS C K ET AL: "Design of PEGylated Soluble Tumor Necrosis Factor Receptor Type I (PEG sTNF-RI) for Chronic Inflammatory Diseases", ADVANCED DRUG DELIVERY REVIEWS, vol. 55, 2003, pages 1315 - 1336, XP003008526  
• [A] WAN ET AL: "An enzyme-linked immunosorbent assay for host cell protein contaminants in recombinant PEGylated staphylokinase mutant SY161", JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, vol. 28, 2002, pages 953 - 963, XP002987234  
• [A] DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2002, LEE H ET AL: "Preparation and characterization of mono-PEGylated epidermal growth factor: Evaluation of in vitro biologic activity", XP002562904, Database accession no. PREV200200438985 & LEE H ET AL, PHARMACEUTICAL RESEARCH, vol. 19, no. 6, 2002, pages 845 - 851  
• See references of WO 2007082482A1

Cited by  
CN110124051A; EP2964761A4; US9803185B2; US11235037B2; US10463721B2; USRE48805E; US9333268B2; US9731028B2; US9789170B2; US10525142B2

Designated contracting state (EPC)  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

Designated extension state (EPC)  
AL BA HR RS

DOCDB simple family (publication)  
**EP 1987838 A1 20081105; EP 1987838 A4 20100224; EP 1987838 B1 20160113**; AU 2007207267 A1 20070726; AU 2007207267 B2 20120628; CA 2637687 A1 20070726; CA 2637687 C 20150714; CN 101002945 A 20070725; CN 101002945 B 20120905; JP 2009523433 A 20090625; NO 20083288 L 20081020; US 2010303893 A1 20101202; WO 2007082482 A1 20070726; WO 2007082482 B1 20070907

DOCDB simple family (application)  
**EP 07702135 A 20070119**; AU 2007207267 A 20070119; CA 2637687 A 20070119; CN 200610011246 A 20060120; CN 2007000203 W 20070119; JP 2008550618 A 20070119; NO 20083288 A 20080724; US 16149407 A 20070119